Text Size

The Effect of Liquorice on Plasma Potassium

This study has been terminated.
(When 9 subjects of targeted 12 subjects had been studied, no changes in plasma potassium were detected and it was deemed futile to continue with enrolment.)
Sponsor:
Information provided by:
University of Oulu
ClinicalTrials.gov Identifier:
NCT00927017
First received: June 22, 2009
Last updated: April 6, 2010
Last verified: April 2010
History of Changes
  Purpose

The hypothesis is that liquorice lowers plasma potassium. This study aims to elucidate the dose-response of this effect with two doses of liquorice (66 grams or 102 grams) per day for two weeks.


Condition Intervention
Healthy
 Other: Liquorice 66 g/day
Other: Liquorice 102 g/day

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Official Title: Lakritsin Vaikutus Kaliumpitoisuuteen

Resource links provided by NLM:

MedlinePlus related topics: Potassium
Drug Information available for: Glycyrrhiza
U.S. FDA Resources

Further study details as provided by University of Oulu:

Primary Outcome Measures:
  • Change in plasma potassium [ Time Frame: 1 week, 2 weeks ] [ Designated as safety issue: Yes ]

Enrollment: 9
Study Start Date: June 2009
Study Completion Date: March 2010
Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Liquorice 66 g/day
Liquorice given 66 grams per day for two weeks
 Other: Liquorice 66 g/day
Liquorice 66 g/day for two weeks
Other Name: Pepe Original liquorice
Active Comparator: Liquorice 102 g/day
Liquorice given 102 grams per day for two weeks
 Other: Liquorice 102 g/day
Liquorice 102 g/day for two weeks
Other Name: Pepe Original liquorice

  Eligibility

Ages Eligible for Study:   18 Years to 40 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • healthy volunteers
  • age 18-40

Exclusion Criteria:

  • any continuous medication
  • hypertension or hypotension
  • allergy to liquorice
  • pregnancy or lactation
  • difficult venipuncture
  • drug or alcohol abuse
  • participation in pharmaceutical trial
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00927017

Locations
Finland
Oulu University Hospital
Oulu, Finland, 90220
Sponsors and Collaborators
University of Oulu
Investigators
Principal Investigator: Janne Hukkanen, MD, PhD Oulu University Hospital, Department of Internal Medicine
  More Information

No publications provided

Responsible Party: Janne Hukkanen, Oulu University Hospital, Department of Internal Medicine
ClinicalTrials.gov Identifier: NCT00927017     History of Changes
Other Study ID Numbers: Lakritsi-2
Study First Received: June 22, 2009
Last Updated: April 6, 2010
Health Authority: Finland: Ethics Committee

Keywords provided by University of Oulu:
Healthy volunteers

ClinicalTrials.gov processed this record on June 18, 2013